ANAB — AnaptysBio Balance Sheet
0.000.00%
HealthcareAdventurousMid CapNeutral
- $707.95m
- $264.98m
- $63.18m
Annual balance sheet for AnaptysBio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2017 December 31st | 2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 248 | 427 | 374 | 394 | 548 |
Net Total Receivables | 1.6 | 0.174 | 0 | — | 0.876 |
Prepaid Expenses | |||||
Total Current Assets | 253 | 434 | 378 | 397 | 554 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.665 | 1.45 | 3.02 | 2.13 | 21.8 |
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 329 | 509 | 435 | 417 | 643 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 14.1 | 21.8 | 29.5 | 19.8 | 16.1 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 21.8 | 22.6 | 30.2 | 19.8 | 287 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 308 | 486 | 405 | 397 | 356 |
Total Liabilities & Shareholders' Equity | 329 | 509 | 435 | 417 | 643 |
Total Common Shares Outstanding |